Evidence map›Paper›PMID 42237139›Full record

ReviewCritical care (London, England)2026

Hyperlactatemia in sepsis and shock: a renal metabolic perspective.

Didier Payen, Thomas Rimmelé, Hernando Gómez

Abstract readReview
In one paragraph

Review in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Didier PayenDepartment of Infectious Diseases, Hôpital Universitaire l'Archet, 151, route Saint-Antoine de Ginestière, Nice Cedex 3, 23079 - 06202, CS, France. dpayen1234@gmail.com.
Thomas RimmeléAnesthesiology and Intensive Care Medicine, Pasteur Hospital, Université Côte d'Azur-CHU de Nice, UR2CA, Equipe CARRES, Nice, France.
Hernando GómezDepartment of Critical Care Medicine, Center for Critical Care Nephrology, CRISMA, University of Pittsburgh, Pittsburgh, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperlactatemia is a frequent finding in critically ill patients and is traditionally interpreted as a marker of tissue hypoxia and anaerobic metabolism. However, in sepsis, septic shock, and other states of circulatory failure - including post-cardiac arrest syndrome - elevated lactate concentrations often occur despite preserved arterial oxygenation and adequate oxygen delivery. Increasing evidence indicates that lactate is a central metabolic intermediate whose circulating concentration reflects the balance between stress-induced production, cellular utilization, and organ clearance. While hepatic metabolism has long been considered the dominant pathway for lactate disposal, the kidneys - particularly proximal tubular cells - play a major and often underappreciated role in lactate utilization and clearance. Acute kidney injury (AKI), a common complication of sepsis, directly alters systemic lactate homeostasis. In this narrative review, we synthesize current knowledge on lactate biology in critical illness and examine the contribution of renal metabolism to hyperlactatemia in patients with sepsis-induced AKI. We propose that lactate should be interpreted as an integrated metabolic signal reflecting systemic stress and impaired clearance - rather than as a surrogate for hypoxia alone - with important implications for the management of septic AKI. The potential of urinary lactate as a marker of proximal tubular metabolic dysfunction and the emerging role of protein lactylation in modulating the inflammatory-to-reparative phenotypic transition are also discussed.

Indexed as

HyperlactatemiaKidneyLactic AcidSepsisShockAcute Kidney InjuryBiomarkersHumansShock, SepticBiomarkersLactic AcidAcute kidney injuryClearance-limited phenotypeLactate pathwaysRenal cell metabolismSeptic shockUrinary lactate

Identifiers

PMID42237139
PMCPMC13617900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.